Vedolizumab – a gut-selective humanised IgG1 monoclonal antibody – has demonstrated statistically significant differences in clinical remission for patients with moderate-to-severe active CD compared with placebo . However, endoscopic healing has not been previously assessed.
Danese et al.  demonstrated positive effects of vedolizumab on endoscopic remission and healing in CD patients in the phase-3b, single-arm, multicentre VERSIFY study. The subjects were 101 patients with moderate-to-severe active CD (≥3 months; CDAI 220-450; SES-CD ≥7; ≥1 mucosal ulceration on centrally read endoscopy). They had previously experienced treatment failure with corticosteroids, IMM, and/or at least one TNF antagonist. Treatment included open-label standard induction dose of IV vedolizumab 300 mg on day 1, and at weeks 2, 6, 14, 22, up to week 26. They also underwent screening colonoscopy at weeks 14 and 26 with a central reader performing the endoscopic evaluatio...
Please login to read the full text of the article.
If you have no account yet, please register now.
« SLC12A2 potential marker of dysplasia associated to inflammation in UC Next Article
Genetic predisposition for gut barrier dysfunction »